AbbVie Inc. $ABBV Stock: Harbour Investments Inc. Cuts Position

Harbour Investments Inc. trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 5.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 210,059 shares of the company’s stock after selling 11,603 shares during the quarter. AbbVie accounts for approximately 0.8% of Harbour Investments Inc.’s portfolio, making the stock its 22nd largest holding. Harbour Investments Inc.’s holdings in AbbVie were worth $54,949,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp lifted its position in AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. Fisher Asset Management LLC boosted its holdings in AbbVie by 252.6% in the 3rd quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock valued at $8,760,498,000 after purchasing an additional 23,991,451 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in AbbVie by 0.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after purchasing an additional 106,091 shares during the period. Legal & General Group Plc acquired a new position in AbbVie during the 2nd quarter worth approximately $2,905,952,000. Finally, Deutsche Bank AG increased its position in AbbVie by 13.0% during the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after purchasing an additional 1,241,587 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting AbbVie

Investors following ABBV have been watching these stories:

• Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Positive Sentiment: AbbVie licensed Nxera Pharma’s EP4 agonist program for inflammatory bowel disease. The deal adds a potential pipeline asset, though its milestones depend on future development and other conditions. AbbVie Deal Altering the Investment Case for Nxera Pharma
• Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

Analysts Set New Price Targets

ABBV has been the subject of a number of analyst reports. Bank of America reissued a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Argus lifted their price target on AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. UBS Group upped their price objective on AbbVie from $275.00 to $295.00 and gave the stock a “neutral” rating in a report on Monday, November 2nd. Oppenheimer increased their price objective on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Finally, JPMorgan Chase & Co. increased their price objective on AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $297.46.

Insider Activity at AbbVie

In related news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the sale, the executive vice president owned 83,171 shares in the company, valued at $24,419,005.60. This represents a 32.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by company insiders.

AbbVie Stock Performance

ABBV stock traded up $0.73 during trading on Friday, reaching $295.18. 3,259,920 shares of the company were exchanged, compared to its average volume of 5,279,493. The company has a market cap of $521.76 billion, a P/E ratio of 50.81, a PEG ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $302.93. The stock’s 50 day moving average price is $275.51 and its 200 day moving average price is $240.91.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The company had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. During the same period in the prior year, the business posted $1.86 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities research analysts forecast that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. AbbVie’s dividend payout ratio is presently 125.30%.

About AbbVie

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.